Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences’ Chief Comm & Corp Aff Officer Johanna Mercier reported routine equity compensation activity. She exercised 6,617 restricted stock units into the same number of common shares, with 3,216 shares withheld at a price of 148.5600 per share to cover tax obligations, leaving her with 134,779 common shares held directly.
Mercier also received new awards: 9,590 restricted stock units and 35,880 non-qualified stock options exercisable at 148.5600 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly.
Gilead Sciences EVP Keeley M Cain Wettan reported routine equity compensation changes. On March 10, 2026, 1,246 restricted stock units converted into the same number of common shares, increasing her direct common stock holdings to 5,054 shares after 606 shares were withheld to cover taxes.
She also received 5,050 new restricted stock units and 18,885 non-qualified stock options exercisable at $148.56 per share, expiring in 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting quarterly at 6.25% until fully vested.
Gilead Sciences SVP receives new equity awards. Senior Vice President of Controllership Erin Burkhart was granted 2,355 restricted stock units and 5,455 non-qualified stock options, each tied to Gilead common stock. Both awards have a four-year vesting schedule, with 25% vesting after one year and the remainder vesting quarterly. Following the grant, Burkhart directly holds 11,245 restricted stock units and 5,455 stock options with a $148.56 exercise price, providing long-term, performance-linked compensation rather than immediate market purchases or sales.
Gilead Sciences Chairman & CEO Daniel O'Day reported routine equity compensation changes. He exercised 20,026 restricted stock units into the same number of common shares, with 9,767 shares withheld to cover tax obligations, leaving him with 652,567 common shares held directly.
O'Day also received new equity awards: 32,815 restricted stock units and 122,755 non-qualified stock options exercisable at $148.56 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly until fully vested.
Gilead Sciences Chief Medical Officer Dietmar Berger reported multiple equity compensation transactions. He exercised 2,133 restricted stock units into common shares, with 1,063 of those shares withheld at $148.56 per share to cover tax obligations rather than sold on the market.
Berger also received 8,415 new restricted stock units and a grant of 31,475 non-qualified stock options exercisable at $148.56 per share, expiring on March 10, 2036. Following these events, he directly holds 18,982 shares of common stock and 47,461 restricted stock units, all subject to multi-year vesting schedules.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson acquired 11,090 shares of common stock through a grant/award on performance share units. These shares vested after both performance and service conditions were met, bringing his directly held total to 178,869 shares of Gilead common stock.
Mercier Johanna reported acquisition or exercise transactions in this Form 4 filing.
Gilead Sciences executive Johanna Mercier received 11,090 shares of common stock through the vesting of performance share award tranches. These shares relate to awards granted on March 10, 2025 that carried both performance- and service-vesting conditions. After this award, her directly held common stock totals 131,378 shares.
Gilead Sciences Chief Medical Officer Dietmar Berger acquired 8,530 shares of common stock at no cost through a grant/award transaction. These shares relate to specific tranches of performance share awards originally granted on March 10, 2025.
The performance-vesting requirement for these tranches was satisfied on February 27, 2026, when the Compensation and Talent Committee certified that the performance goals were met. Following this award, Berger directly holds a total of 17,912 Gilead common shares.
Gilead Sciences executive reports stock award vesting. EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M acquired 470 shares of Gilead common stock on the reported date at a stated price of $0.00 per share, increasing directly held common stock to 4,414 shares.
The shares relate to specific tranches of performance share awards originally granted on March 10, 2025. These tranches were subject to both performance-vesting and service-vesting conditions, with the performance goals certified as attained by the Compensation and Talent Committee on the reported vesting date.
Gilead Sciences Chairman & CEO Daniel O'Day reported both an equity award and stock sales. He acquired 38,396 shares of common stock at $0.00 per share as part of performance share awards granted on March 10, 2025, which vested after the compensation committee certified performance goals.
On the same date, he sold a total of 10,000 common shares in open-market transactions at prices ranging from about $143.63 to $145.71, under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly held 642,308 shares of Gilead common stock.